Type I interferons (alpha/beta) in immunity and autoimmunity.

By A. Theofilopoulos, R. Baccala, B. Beutler, D. Kono. Annual Review of Immunology, 2005

696 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

The inflammasome: an integrated view (2011, result): “This seems counterintuitive, considering the inflammatory role of type I IFN in several disorders (139) but is in agreement with the widespread use of type I IFN in the treatment of inflammatory and autoimmune conditions.”
Type I interferon inhibits interleukin-1 production and inflammasome activation. (2011, background): “Particular attention has been paid to the anti-inflammatory effects exerted by type I IFN, demonstrated by two lines of evidence (Billiau, 2006; Theofilopoulos et al., 2005).”
Parsing the interferon transcriptional network and its disease associations (2016, unknown): “In addition, the interferon transcriptional signature is found elevated in blood cells in many diseases (Theofilopoulos et al., 2005; Forster, 2012), including bacterial or parasitic infections as might be expected (Berry et al., 2010) but also a range of auto-inflammatory disease like Systemic…”
Trex1 prevents cell-intrinsic initiation of autoimmunity (2008, unknown): “Detection of intracellular DNA by the ISD pathway activates potent type I IFN production, and elevated type I IFNs are a hallmark of AGS and lupus (Crow et al., 2003; Pascual et al., 2006; Theofilopoulos et al., 2005).”